HBM Alpha Therapeutics (HBMAT) is focused on developing innovative antibody therapies for endocrine disorders, specifically targeting congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS). The company is advancing its lead candidate, HAT001, which aims to treat hyperandrogenism in CAH patients without the side effects associated with current treatments, such as Cushing Syndrome. This novel approach seeks to convert the treatment of CAH into a more manageable form akin to primary adrenal insufficiency, allowing for lower and more physiological doses of glucocorticoids. Additionally, HBMAT is developing HAT002 for PCOS, leveraging a shared pathway with CAH to address this common endocrine disorder affecting a significant percentage of women of reproductive age.

The foundation of HBMAT's research and development is built upon the expertise of its Scientific Founder, Dr. Joseph Majzoub, and the antibody discovery capabilities of Harbour BioMed. The company has licensed relevant technologies from Boston Children’s Hospital, enhancing its ability to create precision therapies for endocrine disorders. HBMAT's scientific advisory board includes prominent figures in the field, ensuring a robust approach to tackling the complexities of these conditions. With the recent seed financing, HBMAT is poised to advance its promising programs into clinical trials, aiming to meet the significant unmet medical needs of patients suffering from CAH and PCOS.

United States

HBM Alpha Therapeutics is a company presently developing antibody therapeutics.

Endocrine System Diseases

Metabolic Diseases

HBM Alpha Therapeutics

Congenital adrenal hyperplasia

HBM Drug#1

Antibodies

Biologics

Massachusetts

Therapeutic

HBM Alpha Therapeutics

Company Details